J&J Reports the P-II/III (ENERGY) Trial Data on Imaavy for Warm Autoimmune Hemolytic Anemia (wAIHA)

Why It Matters

The data demonstrate a potential disease‑modifying therapy for wAIHA, a condition lacking approved treatments, and could shift standard care toward antibody‑targeted, steroid‑sparing options.

Key Takeaways

• Imaavy increased hemoglobin by 1 g/dL at week 1 in 30 mg/kg arm
• 66.6% of patients reached Hb ≥10 g/dL and ≥2 g/dL rise by week 24
• Fatigue scores improved by week 2 and stayed low through 24 weeks
• Steroid use declined during the trial, indicating steroid-sparing potential
• FDA granted priority review for Imaavy’s sBLA in wAIHA

Pulse Analysis

Warm autoimmune hemolytic anemia remains an orphan indication with no FDA‑approved therapies, forcing clinicians to rely on high‑dose steroids that carry significant long‑term toxicity. Imaavy, a Fc‑engineered anti‑CD38 antibody, aims to interrupt the pathogenic autoantibody cascade, offering a mechanistic approach that could transform patient outcomes. By targeting the underlying immune dysregulation, the drug aligns with a broader industry shift toward precision immunotherapies for hematologic disorders.

The ENERGY trial enrolled 115 adults across two dosing schedules, comparing Imaavy to placebo over 24 weeks before transitioning all participants into an open‑label extension lasting up to 144 weeks. The 30 mg/kg arm delivered a rapid hemoglobin boost of 1 g/dL at week 1, and 66.6% of patients achieved both a hemoglobin level of at least 10 g/dL and a ≥2 g/dL increase by week 24. Notably, fatigue scores improved within two weeks and remained better than baseline throughout the study, while steroid consumption fell, suggesting a meaningful steroid‑sparing effect.

Regulatory momentum is strong: the U.S. Food and Drug Administration granted priority review for Imaavy’s supplemental Biologics License Application, reflecting the high unmet medical need. If approved, Imaavy could capture a niche yet lucrative market, given the chronic nature of wAIHA and the cost burden of ongoing steroid therapy. The upcoming EHA 2026 presentation will likely attract investor interest and set the stage for potential partnerships or licensing deals, positioning J&J as a leader in next‑generation autoimmune hematology treatments.